Literature DB >> 20578151

American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis.

Marina G Silveira1, Elizabeth M Brunt, Jenny Heathcote, Gregory J Gores, Keith D Lindor, Marlyn J Mayo.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20578151     DOI： 10.1002/hep.23637

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  17 in total

1.  Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis.

Authors:  Ellina Lytvyak; Ishwar Hosamani; Aldo J Montano-Loza; Lynora Saxinger; Andrew L Mason
Journal:  Can Liver J       Date:  2019-01-09

Review 2.  Combination antiretroviral studies for patients with primary biliary cirrhosis.

Authors:  Ellina Lytvyak; Aldo J Montano-Loza; Andrew L Mason
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  Jelena S Rudic; Goran Poropat; Miodrag N Krstic; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis.

Authors:  Manabu Hayashi; Kazumichi Abe; Masashi Fujita; Ken Okai; Atsushi Takahashi; Yoshihiro Nozawa; Hiromasa Ohira
Journal:  Med Mol Morphol       Date:  2018-01-29       Impact factor: 2.309

5.  Transplanted human amniotic membrane-derived mesenchymal stem cells ameliorate carbon tetrachloride-induced liver cirrhosis in mouse.

Authors:  DingGuo Zhang; MinYue Jiang; DengShun Miao
Journal:  PLoS One       Date:  2011-02-04       Impact factor: 3.240

6.  Predictors of liver failure in primary biliary cirrhosis.

Authors:  Pan Zhao; Wei-wei Liu; Jin-feng Li; Chun-ya Wang; Hao Wang; Jun Xu; Rui-fang Wang; Hao-zhen Yang; Cheng Jin; Zhen-man Wei
Journal:  Ups J Med Sci       Date:  2014-11-28       Impact factor: 2.384

7.  A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Authors:  Lu Wang; Guan-ya Guo; Jing-bo Wang; Xin-min Zhou; Qiong Yang; Zhe-yi Han; Qiang Li; Jing-wen Zhang; Yun Cai; Xiao-li Ren; Xia Zhou; Rui-Rui Chen; Yong-quan Shi; Ying Han; Dai-ming Fan
Journal:  Sci Rep       Date:  2015-04-20       Impact factor: 4.379

Review 8.  Recent developments in the management of idiopathic cholestatic liver disease.

Authors:  Mohamad H Imam; Emma Weeding; Keith D Lindor
Journal:  Ann Gastroenterol       Date:  2012

9.  Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.

Authors:  V Papastergiou; E A Tsochatzis; M Rodriguez-Peralvarez; M Rodriquez-Peralvarez; E Thalassinos; G Pieri; P Manousou; G Germani; C Rigamonti; V Arvaniti; S Karatapanis; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2013-10-05       Impact factor: 8.171

10.  MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients.

Authors:  Xiaomei Wang; Xiaoyu Wen; Jingjing Zhou; Yue Qi; Ruihong Wu; Yao Wang; Yiwen Kui; Rui Hua; Qinglong Jin
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.